JP2014506231A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506231A5
JP2014506231A5 JP2013530249A JP2013530249A JP2014506231A5 JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5 JP 2013530249 A JP2013530249 A JP 2013530249A JP 2013530249 A JP2013530249 A JP 2013530249A JP 2014506231 A5 JP2014506231 A5 JP 2014506231A5
Authority
JP
Japan
Prior art keywords
composition
cancer
protein
composition according
smad7
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530249A
Other languages
English (en)
Japanese (ja)
Other versions
JP6124791B2 (ja
JP2014506231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/052499 external-priority patent/WO2012040295A2/en
Publication of JP2014506231A publication Critical patent/JP2014506231A/ja
Publication of JP2014506231A5 publication Critical patent/JP2014506231A5/ja
Application granted granted Critical
Publication of JP6124791B2 publication Critical patent/JP6124791B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530249A 2010-09-22 2011-09-21 Smad7の治療的適用 Expired - Fee Related JP6124791B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38544510P 2010-09-22 2010-09-22
US61/385,445 2010-09-22
PCT/US2011/052499 WO2012040295A2 (en) 2010-09-22 2011-09-21 Therapeutic applications of smad7

Publications (3)

Publication Number Publication Date
JP2014506231A JP2014506231A (ja) 2014-03-13
JP2014506231A5 true JP2014506231A5 (https=) 2014-11-13
JP6124791B2 JP6124791B2 (ja) 2017-05-10

Family

ID=45874343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530249A Expired - Fee Related JP6124791B2 (ja) 2010-09-22 2011-09-21 Smad7の治療的適用

Country Status (7)

Country Link
US (3) US9084746B2 (https=)
EP (2) EP3536337A1 (https=)
JP (1) JP6124791B2 (https=)
CN (2) CN103501803B (https=)
CA (1) CA2849382C (https=)
IL (1) IL225406B (https=)
WO (1) WO2012040295A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3536337A1 (en) 2010-09-22 2019-09-11 The Regents of the University of Colorado, a body corporate Therapeutic applications of smad7
CN105358704B (zh) * 2013-03-08 2020-01-03 科罗拉多大学董事会 Ptd-smad7治疗剂
CA2983808C (en) * 2015-04-23 2022-03-22 Washington State University Smad7 gene delivery as a therapeutic
KR101853923B1 (ko) * 2016-01-25 2018-05-02 연세대학교 산학협력단 Smad 단백질을 포함하는 자가 면역 질환 치료용 조성물, Smad 단백질을 포함하는 융합 단백질, 이를 제조하기 위한 벡터, 및 이의 제조 방법
US10772813B2 (en) 2016-06-03 2020-09-15 Colradel, LLC Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
US20200332302A1 (en) * 2017-12-30 2020-10-22 The Regents Of The University Of Colorado, A Body Corporate Therapeutics of ptd-smad7 fusion proteins
WO2019133950A1 (en) * 2017-12-30 2019-07-04 The Regents Of The University Of Colorado, A Body Corporate Smad7 for treatment and prevention of posterior capsule opacification
CA3157375A1 (en) * 2019-10-29 2021-05-06 The Trustees Of The University Of Pennsylvania Automated and precise device for dental plaque detection, monitoring and removal

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
ES2091916T3 (es) * 1989-12-21 1996-11-16 Whitehead Biomedical Inst Metodo para suministrar moleculas en el interior de celulas eucarioticas.
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
WO1994002620A2 (en) 1992-07-27 1994-02-03 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5436222A (en) 1993-03-15 1995-07-25 The Research Foundation Of State University Of New York Use of platelet factor 4 to treat inflammatory diseases
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
GB2320431B (en) 1996-12-20 2000-08-30 Johnson & Johnson Medical Compositions for the treatment of chronic wounds
US6251628B1 (en) 1997-05-20 2001-06-26 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding Smad7
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
WO1999050296A1 (en) * 1998-03-27 1999-10-07 Eli Lilly And Company Treatment and prevention of vascular disease
US8466134B1 (en) 1998-06-26 2013-06-18 Athena Neurosciences, Inc. Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6998240B2 (en) * 2001-06-11 2006-02-14 Wisconsin Alumni Research Foundation Screen for selective inhibitors or activators of Smad protein function
AUPR638101A0 (en) 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
EP1545669B1 (en) 2002-09-06 2011-11-09 3M Innovative Properties Company Metering valve for a metered dose inhaler providing consistent delivery
KR100472938B1 (ko) * 2002-10-31 2005-03-11 학교법인 한림대학교 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도
AU2004281309A1 (en) * 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of ES cell self-renewal and lineage specification, and medium therefor
US9757461B2 (en) * 2005-01-14 2017-09-12 Camurus Ab GnRH analogue formulations
CN101238215A (zh) 2005-04-05 2008-08-06 先锋高级育种国际公司 利用植物病毒密码子偏爱性设计用于在植物中的多肽表达的核酸分子的方法和组合物
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
WO2008105925A2 (en) 2006-09-01 2008-09-04 Oregon Health & Science University COMPOUNDS AND METHODS FOR MODULATING β-CATENIN/SMAD-7 INTERACTIONS
US20080114287A1 (en) * 2006-11-14 2008-05-15 Kar Neng Lai Ultrasound Microbubble Mediated Genes Delivery System
SG188904A1 (en) * 2008-03-17 2013-04-30 Scripps Research Inst Combined chemical and genetic approaches for generation of induced pluripotent stem cells
US8591961B2 (en) * 2008-09-04 2013-11-26 Allergan, Inc. Aesthetic treatment of scars and aging skin
US20110152352A1 (en) * 2008-06-10 2011-06-23 Tufts University Smad proteins control drosha-mediated mirna maturation
US20100184033A1 (en) * 2008-07-16 2010-07-22 West Michael D Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby
EP3536337A1 (en) 2010-09-22 2019-09-11 The Regents of the University of Colorado, a body corporate Therapeutic applications of smad7
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CN105358704B (zh) 2013-03-08 2020-01-03 科罗拉多大学董事会 Ptd-smad7治疗剂

Similar Documents

Publication Publication Date Title
JP2014506231A5 (https=)
Dragan et al. Polysaccharides constructed hydrogels as vehicles for proteins and peptides. A review
Hua et al. Tumors vs. chronic wounds: an immune cell's perspective
Bruno et al. Orchestration of angiogenesis by immune cells
MX2021015834A (es) Nuevas variantes de interleucina-2 para el tratamiento de cancer.
JP2013067645A5 (https=)
JP2015505843A5 (https=)
BR112017027985A2 (pt) peptídeos terapêuticos e métodos de uso dos mesmos
NZ707328A (en) Virus-containing formulation and use thereof
JP2016517888A5 (https=)
BR112015009504A2 (pt) inibidores de rock
EP4124346A3 (en) Compositions and methods for treating diseases
JP2013508415A5 (https=)
JP2014530873A5 (https=)
WO2015018698A1 (en) Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids
Devaraja Current prospects of molecular therapeutics in head and neck squamous cell carcinoma
Catani et al. Intratumoral immunization by p19Arf and interferon-β gene transfer in a heterotopic mouse model of lung carcinoma
Ramadhani et al. Anthocyanin, tartaric acid, ascorbic acid of roselle flower (Hibiscus sabdariffa L.) for immunomodulatory adjuvant therapy in oral manifestation coronavirus disease-19: An immunoinformatic approach
JP2021504404A5 (https=)
JP2016510596A5 (https=)
Jin et al. Cellular senescence in metastatic prostate cancer: A therapeutic opportunity or challenge
WO2016122806A8 (en) Compositions and methods of using a soluble tnf-alpha receptor modified for increased half-life
JP2021505669A5 (https=)
JP2015044878A5 (https=)
CN103251600B (zh) 2-氨基-4-(3′-氰基-4′-吡咯烷基)苯基嘧啶化合物的抗肿瘤应用